Novartis has announced plans to spin off its eye-care unit Alcon into a standalone entity.
The Swiss drug giant said it is seeking shareholder approval for the move, after a strategic review concluded spinning off the business would be consistent with Novartis’ strategy of focusing as a medicines company.
The Alcon ophthalmology pharmaceuticals portfolio – which made 2017 sales of $4.6 billion and includes the potential blockbuster RTH258 (brolucizumab) for neovascular AMD and diabetic macular edema - will remain in house.
Read more:http://www.pharmatimes.com/news/novartis_to_spin_off_eye_unit_alcon_1242441